Motif Bio is a clinical stage biopharmaceutical company which specializes in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings. Motif is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram positive and Gram negative bacteria.
Companies To Watch
XXII 1.39 +0.01 CKPT 10.25 +0.00 CPHR 2.9901 +0.0000 CFRX 1.40 -0.10 CRBP 6.45 -0.30 DMPI 2.20 -0.10 DVAX 5.70 +0.15 FBIO 3.95 +0.11 KERX 6.46 +0.04 MTNB 3.00 -0.03 MDGN 5.57 +0.17 MNOV 5.95 -0.10 MTFB 8.99 +0.59 PRQR 5.00 +0.05 STML 8.45 +0.10 SYN 0.6068 +0.0148 TGTX 12.05 +0.15 THLD 0.4693 +0.0093 TNXP 4.46 +0.11 VSTM 2.37 +0.00 ZIOP 6.29 -0.28 2017-05-26 16:01
- Tonix Pharmaceuticals to Present Additional Clinical Results of Military-Related PTSD Study at the 2017 American Society of Clinical Psychopharmacology Annual Meeting
- Tonix Pharmaceuticals Presented Analyses of Potential Moderators of Treatment Response to U.S. FDA-Designated Breakthrough Therapy for PTSD, TNX-102 SL, in Phase 2 AtEase Study in Military-Related PTSD
- Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol